Improved risk stratification in prostate testing could ensure effective resource allocation, according to results from the OPT Stockholm3 study. In the population-based study, Ugo Falagario and colleagues (University of Foggia, Foggia, Italy) assessed whether reflex testing with Stockholm3 after PSA testing could reduce the proportion of men referred for MRI versus a PSA-only pathway. The OPT Stockholm3 pathway invited all men in the Region Stockholm Gotland in 2024 (born in 1974; Stockholm3 testing if PSA ≥2 ng/mL and if Stockholm3 ≥15 MRI) and 2023 (born in 1973; MRI if PSA ≥3 ng/mL).
The Lancet Oncology published a clinical update in Oncology on 19 Mar 2026.
The item focuses on 41st Annual European Association of Urology Congress 2026.
Review the original article for the full source wording and details.